# US 2013/0252882 A1 · Antimicrobial 4-oxoquinolizines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252882 A1
- Document ID: US20130252882A1
- Status: Published application
- Kind: A1
- Application number: 13/823,187
- Filed: 2012-01-31
- Published: 2013-09-26
- Earliest claimed: 2011-02-01
- Assignees: Evolva SA
- Inventors: Jutta Heim; Peter Schneider; Patrick Roussel; Daniel Milligan; Christian Bartels; Glenn Dale
- Web page: https://patentgrep.com/patent/US20130252882A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 31/04: Antibacterial agents
- C07D 455/02: containing not further condensed quinolizine ring systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

## Claims

### Claim 1

A pharmaceutical composition comprising a Polymyxin and a 4-oxoquinolizine compound represented by formula (II)
wherein
R1 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, —ORX, —N(RX)2, —C(O)RX, —C(O)ORX, or —C(O)N(RX)2, wherein each RX is independently hydrogen, C1-8 alkyl, or C1-8haloalkyl; and
R7 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 alkoxyl, C1-8 haloalkyl, heterocyclyl, —OR11, —N(R11)2, or —C(O)N(R11)2, wherein each R11 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl; and
R8 is a C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C1-8 alkyl, —OR21, —N(R21)2, or —C(O)OR21, wherein each R21 is independently hydrogen or C1-8 alkyl; and
R9 is (CH2)n—COOH or (CH2)n—COO—R10, wherein n is a integer in the range of 0 to 3 and R10 is hydrogen or a carboxyl protecting group; and
Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8)alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY, wherein RY is nitro, cyano, —ORY1, —SRY1, —N(RY1)2, —C(O)RY1, —C(O)ORY1, —C(O)N(RY1)2, —OC(O)RY1, —OC(O)ORY1, —OC(O)N(RY1)2, —N(RY1)C(O)RY1, —N(RY1)C(O)ORY1, —N(RY1)C(O)N(RY1)2, —S(O)2RY1, —S(O)2ORY1, —S(O)2N(RY1)2, —OS(O)2RY1, —OS(O)2ORY1, —OS(O)2N(RY1)2, —N(RY1)S(O)2RY1, —N(RY1)S(O)2ORY1, or —N(RY1)S(O)2N(RY1)2, wherein each RY1 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the 4-oxoquinolizine compound is a compound of formula IIIa:
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, —ORX, —N(RX)2, —C(O)RX, —C(O)ORX, or —C(O)N(RX)2, wherein each RX is independently hydrogen, C1-8 alkyl, or C1-8haloalkyl; and
R7 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 alkoxyl, C1-8 haloalkyl, heterocyclyl, —OR11, —N(R11)2, or —C(O)N(R11)2, wherein each R11 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl; and
Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8)alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY, wherein RY is nitro, cyano, —ORY1, —SRY1, —N(RY1)2, —C(O)RY1, —C(O)ORY1, —C(O)N(RY1)2, —OC(O)RY1, —OC(O)ORY1, —OC(O)N(RY1)2, —N(RY1)C(O)RY1, —N(RY1)C(O)ORY1, —N(RY1)C(O)N(RY1)2, —S(O)2RY1, —S(O)2ORY1, —S(O)2N(RY1)2, —OS(O)2RY1, —OS(O)2ORY1, —OS(O)2N(RY1)2, —N(RY1)S(O)2RY1, —N(RY1)S(O)2ORY1, or —N(RY1)S(O)2N(RY1)2, wherein each RY1 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the 4-oxoquinolizine compound is a compound of formula IIIb:
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, —ORX, —N(RX)2, —C(O)RX, —C(O)ORX, or —C(O)N(RX)2, wherein each RX is independently hydrogen, C1-8 alkyl, or C1-8haloalkyl; and
R8 is a C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, or heteroaryl, wherein the cycloalkyl and heteroaryl are optionally substituted with one to five groups that are each independently halogen, C1-8 alkyl, —OR21, —N(R21)2, or —C(O)OR21, wherein each R21 is independently hydrogen or C1-8 alkyl; and
Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8)alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY, wherein RY is nitro, cyano, —ORY1, —SRY1, —N(RY1)2, —C(O)RY1, —C(O)ORY1, —C(O)N(RY1)2, —OC(O)RY1, —OC(O)ORY1, —OC(O)N(RY1)2, —N(RY1)C(O)RY1, —N(RY1)C(O)ORY1, —N(RY1)C(O)N(RY1)2, —S(O)2O(RY1), —S(O)2ORY1, —S(O)2N(RY1)2, —OS(O)RY1, —OS(O)2ORY1, —OS(O)2N(RY1)2, —N(RY1)S(O)2RY1, —N(RY1)S(O)2ORY1, or —N(RY1)S(O)2N(RY1)2, wherein each RY1 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the 4-oxoquinolizine compound is a compound of formula IIIc:
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, —ORX, —N(RX)2, —C(O)RX, —C(O)ORX, or —C(O)N(RX)2, wherein each RX is independently hydrogen, C1-8 alkyl, or C1-8haloalkyl; and
Y is heterocyclyl, aryl, or heteroaryl, each optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8)alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY, wherein RY is nitro, cyano, —ORY1, —SRY1, —N(RY1)2, —C(O)RY1, —C(O)ORY1, —C(O)N(RY1)2, —OC(O)RY1, —OC(O)ORY1, —OC(O)N(RY1), —N(RY1)C(O)ORY1, —N(RY1)C(O)ORY1, —N(RY1)C(O)N(RY1)2, —S(O)2RY1, —S(O)2ORY1, —S(O)2N(RY1)2, —OS(O)2RY1, —OS(O)2ORY1, —OS(O)2N(RY1)2, —N(RY1)S(O)2RY1, —N(RY1)S(O)2ORY1, or —N(RY1)S(O)2N(RY1)2, wherein each RY1 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 5)

The pharmaceutical composition according to claim 5, wherein R1 is hydrogen or halogen.

### Claim 9 (depends on 5)

The pharmaceutical composition according to claim 5, wherein Y is aryl optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8) alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, C(O)RY1, or —C1-8 alkyl-RY.

### Claim 10 (depends on 5)

The pharmaceutical composition according to claim 5, wherein Y is phenyl substituted with one group which is halogen, cyano, —ORY1, —SRY1, —N(RY1)2, C1-8 alkyl, —C1-8 alkyl-N(RY1)2, or —C1-8 alkyl-ORY1, and optionally substituted by one to two groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8) alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY.

### Claim at position 10

11-16. (canceled)

### Claim 17 (depends on 5)

The pharmaceutical composition according to claim 5, wherein Y is a 5-membered or 6-membered heteroaryl optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8)alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY.

### Claim at position 12

18-22. (canceled)

### Claim 23 (depends on 5)

The pharmaceutical composition according to claim 5, wherein Y is a bicyclic heteroaryl optionally substituted by one to five groups that are each independently halogen, C1-8 alkyl, C1-8 haloalkyl, C3-8cycloalkyl, heterocyclyl, aryl, heteroaryl, C3-8cycloalkyl(C1-8) alkyl, heterocyclyl(C1-8)alkyl, aryl(C1-8)alkyl, heteroaryl(C1-8)alkyl, —RY, or —C1-8 alkyl-RY.

### Claim at position 14

24-29. (canceled)

### Claim 30 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the 4-oxoquinolizine compound is selected from the group consisting of compounds 1 to 90 of Table 1.

### Claim 31 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the Polymyxin is selected from the group consisting of Polymyxin B and Polymyxin E.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polymyxin is present in a subinhibitory concentration.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A method of treatment of a bacterial infection in an individual in need thereof, said method comprising administering the composition according to claim 1 to said individual.

### Claim 36 (depends on 35)

The method according to claim 35, wherein said bacterial infection is infection by a multiresistant strain.

### Claim at position 22

37-38. (canceled)

### Claim 39 (depends on 35)

The method according to claim 35, wherein the composition is for treatment of a bacterial infection in an individual in need thereof, and said infection is infection by one or more bacteria of a genus selected from the group consisting of Acinetobacter, Bacillus, Bortadella, Borrelia, Brucella, Camphylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Fransisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Propionibacterium, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio and Yersinia.

### Claim at position 24

40-45. (canceled)

### Claim 46

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, —ORX, —N(RX)2, —C(O)RX, —C(O)ORX, or —C(O)N(RX)2, wherein each RX is independently hydrogen, C1-8 alkyl, or C1-8haloalkyl; and
R2, R3, R4, R5 and R6 each independently are hydrogen, hydroxyl, —(CH2)n—NH—(C═O)—(CH2)m—CH3, —(C═O)—C1-8 alkyl, —(C═O)—C1-8 haloalkyl, halogen, —(CH2)n—NH2, —NH—(CH2)n—CH3, C1-8-alkyl or C1-8 alkoxy, wherein n and m each independently is an integer in the range of 0 to 3 and wherein at least one of R2, R3, R4, R5 or R6 is hydroxyl, —(CH2)n—NH—(C═O)—(CH2)n—CH3 or —(C═O)—C1-8 haloalkyl; and
R7 is hydrogen, halogen, cyano, C1-8 alkyl, C1-8 alkoxyl, C1-8 haloalkyl, heterocyclyl, —OR11, —N(R11)2, or —C(O)N(R11)2, wherein each R11 is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl.

### Claim 47 (depends on 46)

The compound according to claim 46, wherein the compound is selected from the group consisting of compounds 56, 61, 63, 64, 66, 70 and 72 of Table 1.

### Claim 48

(canceled)

### Claim 49

A compound of formula (V) or a pharmaceutically acceptable salt thereof,
wherein R1 is hydrogen or fluorine; and
R2, R3, R4 and R5 each individually are selected from the group consisting of hydrogen, (CH2)n-hydroxyl, fluorine, C1-3 alkyl, —(CH2)n—NH2, —NH—(CH2)n—CH3 and a 5 to 6 membered heterocyclic ring, wherein n is an integer in the range of 0 to 2; and
R6 is hydrogen and
R7 is C1-3 alkyl or C1-3 alkoxy; and
Q1, Q2 and Q3 each individually are C or N, wherein at least one of Q1, Q2 and Q3 is N and at least one of Q1, Q2 and Q3 is C, and wherein if Q1 is N, then R3 is not present, and if Q2 is N, then R4 is not present and if Q3 is N, then R5 is not present
with the provisos that
if Q1 is N and Q2 and Q3 are C, then at least one of R2, R4 and R5 is not hydrogen; and
if Q1 is N and Q2 and Q3 are C and R4 is —NH2, then R1 is fluorine and/or R7 is methoxy; and
if Q3 is N and Q2 and Q1 are C, then at least one of R2, R3 and R4 is not hydrogen; and
if Q3 is N and Q2 and Q1 are C and R4 is —NH2, then R1 is fluorine and/or R7 is methoxy.

### Claim 50

(canceled)

### Claim 51 (depends on 49)

The compound according to claim 49, wherein the compound is selected from the group consisting of compounds 55, 57, 58, 59, 60, 65, 78, 79, 84, 87 and 89 of Table I.

### Claim at position 31

52-67. (canceled)

### Claim 68 (depends on 47)

The compound according to claim 47, wherein the compound is compound 72 of Table I.

### Claim 69 (depends on 49)

The compound according to claim 49, wherein the compound is compound 79 of Table I.
